Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a fruit compound clear old cells and fight aging?

NCT ID NCT06431932

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests fisetin, a natural compound found in strawberries and apples, in healthy young adults and older people with multiple chronic diseases. Participants take fisetin or a placebo for two days and are followed for up to three months. The goal is to see if fisetin safely removes senescent (aging) cells and reduces inflammation, which could help manage age-related health problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fisetin (a natural compound from fruits and vegetables)
What this could lead to
If it works, this could point toward a treatment that reduces chronic inflammation and age-related diseases by clearing old, damaged cells.
What could go wrong
This is an early Phase 1/2 trial with only 60 participants, so results may not apply broadly. Fisetin's effects on humans are still uncertain, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy volunteers: Inclusion Criteria: * Aged 20-35 years * suPAR levels \<3.5 ng/mL (± 15% corresponding to assay variation) * Able to cooperate cognitively * Able to read and understand Danish * Women of childbearing potential must use effective contraception Exclusion Criteria: * Body weight \>100 kg * Inability to swallow pills * Pregnant and/or lactating * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial * Presence of known chronic diagnosis * Active acute illness * Prescribed medication, except contraceptives * Previous cancer diagnosis or treatment * Use of senolytic and other "anti-aging" supplements Older patients with multimorbidity: Inclusion Criteria: At screening #1 during hospital admission: * Acutely hospitalized medical patient * Age ≥65 years * suPAR \>5 ng/mL (± 15% corresponding to assay variation) * Multimorbidity (≥2 chronic diagnoses) * Able to cooperate cognitively * Able to read and understand Danish At screening #2 28 days after hospital discharge: * suPAR \>5 ng/mL (± 15% corresponding to assay variation) Exclusion Criteria: At screening #1 during hospital admission: * Body weight \>100 kg * Inability to swallow pills * Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection * Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites * New/active invasive cancer except non-melanoma skin cancers * Active cancer treatment or disseminated cancer * Known condition associated with major immunodeficiency * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Use of senolytic and other "anti-aging" supplements At screening #2 28 days after hospital discharge: * Body weight \>100 kg * CRP \>30 mg/L (± 15% corresponding to assay variation) * Inability to swallow pills * Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial * Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer * Estimated glomerular filtration rate (eGFR) \<15 ml/min/1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury) * Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection * Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites * New/active invasive cancer except non-melanoma skin cancers * Active cancer treatment or disseminated cancer * Known condition associated with major immunodeficiency * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Subjects taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment * Subjects taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment * Subjects taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment * Subjects regularly using drug classes or specific medications or as per clinical judgment * Use of senolytic and other "anti-aging" supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre

    RECRUITING

    Hvidovre, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.